Article
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
All News
Article
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Article
Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.
Article
JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM.
DM affects all races, but it has been suggested that racial and ethnic minority patients may have more severe disease and a different autoantibody profile. This analysis characterizes the clinical features and outcomes of DM in Hispanic and non-Hispanic patients.
Article
CARRA has developed consensus treatment plans for the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with refractory, moderately severe juvenile dermatomyositis. Juvenile dermatomyositis is the most common form of idiopathic, inflammatory myositis in childhood, with an estimated incidence of 3.2 per million children per year in the United States.
Article
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
Article
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Dr. John Cush
Tweet
Chinese study of 62 Systemic JIA pts Rx w/ IV Tocilizumab (34 12 mg/kg; 28 8 mg/kg). Wk12 87% responded (JIA ACR 30w/ no fever); Week 52 results were similar. No deaths or macrophage activation syndrome occurred. https://t.co/qGgMCt597x https://t.co/lFDxAgDHfW
Dr. John Cush
Tweet
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/fHL14rXAQ6 https://t.co/ZagRU62joJ
Dr. John Cush
Tweet
Consensus Guidelines on Pediatric Methotrexate Use
MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects:
-indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF
Dr. John Cush
Tweet
Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders https://t.co/TWx62EhRBl https://t.co/6uhoRowg3n
Dr. John Cush
Tweet
Karolinska genotyping study of 329 JIA pts (oligo 161, Seroneg Poly 87, Seropos poly 12, Stills 24, ERA 22, PsA 19). HLA-DRB1*08 linked to JIA total; The HLA-DRB1*11 to Oligo; ANA+ JIA linked to HLA-DRB1-DQA1-DQB1, HLA-DRB1*11, & HLA-DPB1*02 https://t.co/1yNawNTEys https://t.co/dmmlH0CvRi
Dr. John Cush
Tweet
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Dr. John Cush
Tweet
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis
CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM).
https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip
Dr. John Cush
Tweet
US Childrens Hosp Admission database finds 8588 kids w/ SLE & ≥ 1 hospitalization; 13% for infections, w/ Bacterial pneumonia most common. cSLE In-hospital mortality in 0.4%, but 2% for infection. Highest mortality w/ PJP (21%), fungal infx (21%) https://t.co/fmyRXagCcD https://t.co/yXDMFYhhdP
Dr. John Cush
Tweet
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1
Dr. John Cush
Tweet
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy
Dr. John Cush
Tweet
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush
Tweet
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
